Evidence map›Paper›PMID 31993026›Full record

ArticleFrontiers in microbiology2019

Thioredoxin Reductase 1 Is a Highly Immunogenic Cell Surface Antigen in

Fabiana Freire Mendes de Oliveira, Verenice Paredes, Herdson Renney de Sousa, Ágata Nogueira D'Áurea Moura, Juan Riasco-Palacios, Arturo Casadevall, Maria Sueli Soares Felipe, André Moraes Nicola

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Multi-Omics Profiling ofMicroorganisms · 2023
    Article
  3. One Century of Study: What We Learned aboutJournal of fungi (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Fabiana Freire Mendes de OliveiraFaculty of Medicine, University of Brasília, Brasília, Brazil.
Verenice ParedesFaculty of Medicine, University of Brasília, Brasília, Brazil.
Herdson Renney de SousaFaculty of Medicine, University of Brasília, Brasília, Brazil.
Ágata Nogueira D'Áurea MouraDepartment of Microbiology, Institute of Biomedical Sciences II, University of São Paulo, São Paulo, Brazil.
Juan Riasco-PalaciosFaculty of Medicine, University of Brasília, Brasília, Brazil.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Maria Sueli Soares FelipeGraduate Program in Genomic Sciences and Biotechnology, Catholic University of Brasília, Brasília, Brazil.
André Moraes NicolaFaculty of Medicine, University of Brasília, Brasília, Brazil.
Universidade de Brasília · BRJohns Hopkins University · USUniversidade Católica de Brasília · BRUniversidade de São Paulo · BR

Funding

CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7M
Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
Molecular Characterization of C. neoformans AntibodiesR37AI033142 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2007 to 2016
$3.9M
Clinical and Translational Science AwardKL2TR001071 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SHAMOON, HARRY · 2013 to 2017
$968k
Clinical and Translational Science AwardTL1TR001072 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SHAMOON, HARRY · 2013 to 2017
$909k
NCATS NIH HHS KL2 TR001071NCATS NIH HHS TL1 TR001072NCATS NIH HHS UL1 TR001073NCATS NIH HHS UL1 TR002556NIAID NIH HHS R37 AI033142
6 · The paper itself

Abstract

The increasing number of immunocompromised people has made invasive fungal infections more common. The antifungal armamentarium, in contrast, is limited to a few classes of drugs, with frequent toxicity and low efficacy pointing to the need for new agents. Antibodies are great candidates for novel antifungals, as their specificity can result in lower toxicity. Additionally, the immunomodulatory activity of antibodies could treat the underlying cause of many invasive mycoses, immune disfunction. In a previous comparative genomics study, we identified several potential targets for novel antifungals. Here we validate one of these targets, thioredoxin reductase (TRR1), to produce antibodies that could be useful therapeutic tools. Recombinant TRR1 proteins were produced by heterologous expression in

Indexed as

antibodiesCandida albicanscell wallCryptococcus neoformansParacoccidioides lutziithioredoxin reductase

Identifiers

PMID31993026
PMCPMC6964600
OpenAlexW2999224854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.